Welcome to our dedicated page for ABEONA THERAPEUTICS SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ABEONA THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ABEONA THERAPEUTICS's regulatory disclosures and financial reporting.
Abeona Therapeutics (ABEO) reported Q3 2025 results, reflecting the first months after FDA approval of ZEVASKYN for RDEB. The quarter showed a net loss of $5.2 million, compared with a $30.3 million loss a year ago, as commercialization spending ramped. Year-to-date, the company recorded $91.6 million in net income, largely from a $152.4 million gain on the sale of a Priority Review Voucher.
Liquidity strengthened: cash and cash equivalents were $82.9 million and short‑term investments were $124.2 million as of September 30, 2025. Stockholders’ equity rose to $171.2 million. Q3 operating expenses included R&D $4.2 million and SG&A $19.3 million as the company built out commercial infrastructure and manufacturing capacity. Inventory totaled $4.9 million (raw materials). Warrant liabilities declined to $22.6 million. The company maintained a $20.0 million senior term loan; an amendment on July 18, 2025 reduced the interest rate to a fixed 11.75% and included issuance of 16,473 new warrants. Common shares outstanding were 54,191,361 as of November 7, 2025.
Abeona Therapeutics Inc. (ABEO) furnished quarterly results information. The company reported that it issued a press release regarding its financial results for the quarter ended September 30, 2025, and furnished it under Item 2.02.
The full text of the release is included as Exhibit 99.1. As stated, the information under Item 2.02 and Exhibit 99.1 is furnished and not deemed “filed” for purposes of Section 18 of the Exchange Act, and is not incorporated by reference except as expressly set forth by specific reference.
Abeona Therapeutics (ABEO) CEO and Director Vishwas Seshadri reported a Form 4 transaction. He sold 249 shares of common stock on 10/16/2025 at $5.485 per share, a sale described as to cover tax obligations from the vesting of restricted stock awards.
Following the transaction, he beneficially owns 1,189,818 shares, held directly.
Nantahala Capital Management, LLC and two managers report shared beneficial ownership of 5,184,662 shares of Abeona Therapeutics, representing 9.99% of the outstanding common stock as of 09/30/2025. The total includes 619,997 shares that may be acquired within 60 days upon exercise of warrants. Nantahala reports shared voting and dispositive power over these shares; none are held with sole voting or sole dispositive power. The filing states the holdings are managed in the ordinary course of business and not for the purpose of changing control. Contact and organizational details for Nantahala, and certifications by Nantahala and managers Wilmot B. Harkey and Daniel Mack, are included with signatures dated 10/06/2025.
A Nantahala Capital Partners Schedule 13G filed for ABEONA THERAPEUTICS INC. reports shared beneficial ownership of 5.09% of common stock as of 09/29/2025. Nantahala discloses beneficial ownership of 2,618,462 shares, which includes 179,832 shares exercisable within sixty days. The filing states Nantahala holds no sole voting or dispositive power and reports shared voting and dispositive power for the full amount. The ownership percentage is calculated using a reported outstanding share count of 51,278,539 shares from the issuer's Form 10-Q for the period ended 06/30/2025. Signatures by compliance and management representatives are dated 10/06/2025.
ABEO Form 4 summary: Brendan M. O'Malley, Senior Vice President and Chief Legal Officer of Abeona Therapeutics (ABEO), reported a sale of 9,366 shares of common stock on 09/29/2025 at a weighted average price of $5.3935 per share. After the sale, he beneficially owns 350,763 shares. The filing states the sale was executed to cover tax obligations arising from the vesting of restricted stock awards and that the reported price reflects multiple transactions ranging from $5.35 to $5.46.
Insider sales reported by Vishwas Seshadri, CEO and Director of Abeona Therapeutics (ABEO). The Form 4 shows two non-derivative sales: 19,274 shares sold on 09/29/2025 at a weighted average price of $5.3935 to cover tax obligations from restricted stock vesting, and 25,000 shares sold on 09/30/2025 at a weighted average price of $5.2372 under an existing Rule 10b5-1 trading plan. The reporting persons beneficial ownership decreased from 1,215,067 shares to 1,190,067 shares following these transactions. The filing is signed by Vishwas Seshadri on 10/01/2025.
Joseph Walter Vazzano, Chief Financial Officer of ABEONA THERAPEUTICS INC. (ABEO), reported the sale of 9,035 shares of common stock on 09/29/2025. The disclosed weighted-average price was $5.3935 per share, with individual trade prices ranging between $5.35 and $5.46. The filing states the shares were sold to cover tax obligations arising from the vesting of restricted stock awards. After the reported sale, the reporting person beneficially owned 453,631 shares, held directly. The Form 4 reflects a routine tax-related disposition rather than a market-timing or strategic sale.
Form 144 notice for Abeona Therapeutics, Inc. (ABEO): The filer reports a proposed sale of 44,274 shares of common stock through Stifel Nicolaus & Company, to be executed on 09/29/2025 on Nasdaq with an aggregate market value of $238,792.00. The shares were acquired as 38,800 restricted stock units on 09/28/2025 and payment is noted as cash on 09/29/2025. The filing shows 51,156,736 shares outstanding for the issuer. The form also discloses a sale by Vishwas Seshadri of 69,420 shares on 07/09/2025 for $406,503.00. The notice contains the standard insider representation regarding material nonpublic information.
A Form 144 notice shows a proposed sale of 9,366 shares of common stock of Abeona Therapeutics, Inc. (ticker ABEO) by Brendan O'Malley. The shares are listed with an aggregate market value of $50,516.00 and the filer lists Nasdaq as the exchange. The filing states the shares were acquired as Restricted Stock Units on 09/29/2025 and payment is shown as cash. The table of recent sales also records a sale by Brendan O'Malley of 9,366 shares on 09/22/2025 for gross proceeds of $50,515.00. The notice includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.